AMS Planning, Inc.は北大発ベンチャー認定を受けた核医学スタートアップ企業です

AMS Planning, Inc. Advanced Medical Science Planning, Inc.

About us

Cure Better, Innovation

Advanced Medical Science-Planning, Inc (AMS) is a Japanese nuclear medicine start-up company seeking to transform Japan’s nuclear industry and provide new business and economic growth opportunities following the March 2011 Fukushima Nuclear Power Station Accident.

Pursuant to our corporate mantra “Cure Better, Innovation”, AMS will deploy nuclear medicine based Theranostics, which combines both therapeutic and diagnostic capabilities in one dose for cancer treatment, as well as to pair Theranostics with artificial intelligence to enhance their effectiveness in terms of Precision Oncology.

In connection with executing our disruptive growth strategy, AMS is presently working in the application process to the Pharmaceutical and Medical Devices Agency (PMDA) on a phased approach to bring 68Ga-PSMA-PET diagnosis for prostate cancer to Japan that is available at UCSF and UCLA as a result of the approval from the U.S. Food and Drug Administration on December 01, 2020, and at medical institutions using 68Ga-PSMA-PET as parts of a clinical trial in Europe and Australia. AMS also plans to establish the capability to produce radioisotopes of interest in Japan as part of our overall strategy for Japan and the Asian region. AMS, through its subsidiary Medical Isotope Prime Japan (MIPJ) is also securing long-term, stable supplies of key medical isotopes to enable the development of new treatments by Japanese research institutions and hospitals. This includes alpha therapies using actinium225 (Ac225) which is an isotope that is in high demand, but short supply in Japan and globally.



AMS team is the right mix of passion and experience from diversified industries, including experts in nuclear medicine, business development, and regulatory affairs.
  • (Representative Director, President and CEO)
    Suga founded AMS in 2019 being motivated by his family’s event regarding the minimally invasive heart surgery and his passion for Fukushima's road to recovery, which has led him to focus on the nuclear medicine. Suga has 20 years of business development experience in both regulated and deregulated energy industry and disruptive IT company with a variety of senior business management roles.
    Suga has a bachelor’s and a master’s degree in engineering from Waseda University and an MBA from the Washington University in Saint Louis, Olin School of Business.
  • Toshihide Kubo (Director and Chief Operating Officer)
    Kubo joined AMS in July 2019 as Director and Chief Operating Officer. Kubo has 30 years of strategic investment and business management experience at Marubeni corporation, including as an outside director of Given Imaging Ltd. (now Medtronic).
    Kubo has a bachelor’s degree in engineering from Keio University.
  • Minoru Katsu (CEO Office Manager)
    Katsu joined AMS in Feb 2019 as CEO Office Manager. Katsu has extensive experience in accounting, financing, and business administration for almost 30 years at Mitsubishi Corporation.
    Katsu has a bachelor’s degree in economics from Rikkyo University.
  • Komei Washino, Ph.D. (Chief Technology Officer)
    Washino joined AMS in Dec 2019 as Nuclear Medicine Technical Manager. Washino has 30 years of experience in drug development, research, and commercialization of innovative radiopharmaceuticals. Before AMS, Washino was a Director at Nihon Medi-Physics, held academic appointments as a research professor at Hokkaido University Graduate School of Medicine and visiting researcher at the National Institutes for Quantum and Radiological Science and Technology (QST).
    Dr. Washino received his DVM, Doctor of Veterinary Medicine, and Ph.D. from the Faculty of Veterinary Medicine, Hokkaido University.
  • Noriake Okamoto (Nuclear Medicine Academic Office Manager)
    Okamoto joined AMS in Feb 2019 as Nuclear Medicine Academic Office Manager. Okamoto has spent 40 years in commercial and business development roles in companies in the nuclear medicine sector, beginning his career with Daiichi-RI Pharma (Now Fujifilm Toyama Kagaku) in 1975, including as General Manager for Bristol-Myers Squibb and Dupont. Okamoto also held an academic appointment as a lecturer at CHIBA INSTITUTE OF SCIENCE, Faculty of Risk and Crisis Management, Department of Health and Medical Sciences.
    Okamoto holds a pharmacist license in Japan, a bachelor of pharmacy from Shizuoka Prefectural college of Pharmacy and was a research fellow at Pharmaceutical Science, Tokyo University.
  • Meizo Kusaka, Ph.D. (Regulatory Office Manager)
    Kusaka joined AMS in May 2020 as Regulatory Office Manager. Kusaka has 40 years of experience in regulatory and clinical affairs, beginning his career with Zeria Pharmaceutical KK in 1978, including managerial roles at Marion Merrell Dow K.K. (Now Aventis Pharma Co.), Bristol-Myers Squibb KK, St.Jude Medical Company, and ConvaTec Japan KK. Kusaka also holds an academic appointment as a lecturer at Kyoto Tachibana University, Faculty of Nursing.
    Kusaka received a bachelor of pharmacy from Nihon University, M.S., Pharmacy from Kitasato University, and Ph.D., Pharmacy from Hoshi University. Kusaka holds a pharmacist's license in Japan.
  • Bruno Rossi (Business Development Advisor)
    Bruno Rossi has 30 years of experience in the pharmaceutical industry through positions with the French Embassy in Japan, Ciba-Geigy at the parent company in Basle and its affiliates in Japan and South-East Asia, as a consultant in Singapore and Japan with Coopers & Lybrand Consultants, in senior managerial positions in Japan with Nihon Schering and Bayer Yakuhin (strategic planning, business development & licensing, mergers and acquisitions, business operations, pricing and advocacy). After retiring from Bayer in 2016, Bruno Rossi advised Quintiles Transnational, Cisbio Bioassays and others. For Cerveau Technologies, he is leading the development in Asia of two PET tracers for amyloid and tau imaging, setting up production sites to support multiple clinical studies.

    He graduated from Ecole Supérieure de Commerce de Paris (ESCP) and Institut National des Langues et Civilisations Orientales (INALCO, BA in Japanese) in 1975.
  • Jeff A Miller, J.D. (Advisor)
    Jeff joined AMS in Feb 2019 as an Executive Officer and Chief Legal and Strategy Officer. Jeff entered the US Government in 1999 as a Presidential Management Fellow and has worked principally for the US Departments of State and Energy, the Pacific Northwest National Laboratory as well as the private sector in nuclear energy, infrastructure, and national security programs.  He has worked in all phases of the nuclear fuel cycle, developing strategies for market entry in Japan, and cross-border nuclear business for US and Japan alliance partners.  From 2011-2016 Jeff headed the Department of Energy Office, in the US Embassy Tokyo and helped to build initial US national laboratory and commercial partnerships to support Fukushima clean-up and recovery.
    He is licensed to practice law in Maryland and the District of Columbia.
  • Fumio Okazaki (Nuclear Medicine Manufacturing Advisor)
    Okazaki has 40 years of extensive experience in project management, operations, and GMP manufacturing, including as a Senior Factory Manager at Chiba factory of Fujifilm RI Pharma (Now Fujifilm Toyama Kagaku) with responsibility for quality-controlled manufacturing and overseeing product development of several advanced radiopharmaceuticals.
    He serves on the advisor of several other enterprises, including Atox.


Name of company
Advanced Medical Science-Planning, Inc
23,990,000 JPY
Description of business
Production, import, development and sales of
radio-isotopes and medical devices
1-15-29 Shirokane, Minato-ku Tokyo 108-0072
Email Address